Navigation Links
AcelRx Pharmaceuticals Hires Mark Evashenk as Vice President of Clinical Operations
Date:3/6/2009

REDWOOD CITY, Calif., March 6 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. announced today it has hired Mark Evashenk as Vice President, Clinical Operations. In this new position, Mr. Evashenk will assist in defining developmental strategy, guiding clinical protocol design and study conduct, and managing risk assessment. He will report to Dr. Pamela Palmer, the company's Chief Medical Officer. "We are very fortunate to continue to attract leaders in the pharmaceutical industry; Mark possesses an unparalleled breadth and depth of experience that will be of great value to AcelRx," stated Dr. Palmer. "Mark will play a vital role in overseeing all phases of clinical development, with a particular emphasis on the successful execution of studies planned for our mid- and late-stage product candidates."

Mark has over 25 years of pharmaceutical and device development experience with a focus on project management and clinical operations, most recently as Director of Clinical Operations at ALZA Corporation, a Johnson & Johnson Company. Throughout his career, Mark has managed clinical operations teams for numerous studies worldwide representing all stages of development, including registration studies supporting four successful NDA filings. Mark holds his BS in Environmental Toxicology from UC Davis.

About AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals is a privately held pharmaceutical company dedicated to the development and commercialization of new therapies for the treatment of pain and other conditions where there is an unmet need for improved safety and efficacy. The company applies its proprietary dosage form and delivery technologies to enhance the safety, therapeutic benefit and commercial attractiveness of currently approved compounds.

For additional information about AcelRx Pharmaceuticals visit http://www.acelrx.com.


'/>"/>
SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. AcelRx Pharmaceuticals Reports Positive Results From a Phase 2 Clinical Trial of Sublingual Sufentanil NanoTabs(TM) in Treating Post-Operative Pain
2. AcelRx Pharmaceuticals Hires Roman Skowronski, M.D., Ph.D. as Vice President of Clinical Development
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... TURIN, Italy , April 29, 2016 ... version 5.11, the latest update to its industry-leading treatment ... has shown that Monaco version ... Users can now attain calculation speeds up to four ... Monaco . With the industry,s gold standard ...
(Date:4/28/2016)... MA (PRWEB) , ... April 28, 2016 , ... ... Asymmetrex will deliver a talk on its first-in-class technologies for tissue ... 2016 Meeting on RNAiMicroRNA Biology to Reprogramming & CRISPR-based Genome Engineering ...
(Date:4/27/2016)... ... April 27, 2016 , ... Shimadzu Scientific Instruments (SSI) will ... Marijuana Business Conference and Expo. Shimadzu’s high-performance instruments enable laboratories to test cannabis ... attendees can stop by booth 1021 to learn how Shimadzu’s instruments can help ...
(Date:4/27/2016)... RESEARCH TRIANGLE PARK, N.C. , April ... UTHR ) announced today that Martine Rothblatt , ... will provide an overview and update on the company,s ... Health Care Conference. The presentation will take ... Eastern Time, and can be accessed via a live ...
Breaking Biology Technology:
(Date:3/23/2016)... 2016 Einzigartige ... und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler Kommunikationsdienste, ... SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie einzusetzen. ... Möglichkeit angeboten, im Rahmen mobiler Apps neben ...
(Date:3/18/2016)... --> --> ... & Unmanned Vehicles, Physical infrastructure and Perimeter Surveillance & Detection ... border security market and the continuing migration crisis in the ... has led visiongain to publish this unique report, ... defence & security companies in the border security ...
(Date:3/14/2016)... -- NXTD ) ("NXT-ID" or the "Company"), a ... airing of a new series of commercials on Time Warner ... st .  The commercials will air on Bloomberg TV, Fox ... Street show. --> NXTD ) ("NXT-ID" or the ... announces the airing of a new series of commercials on ...
Breaking Biology News(10 mins):